Licofelone

Licofelone is a dual COX/LOX inhibitor^[1][2] that was studied in clinical trials as a treatment for osteoarthritis^[3] and which was under development by Merckle GmbH with partners Alfa Wassermann and Lacer.

Legal status

• Investigational

CAS Number

• 156897-06-2

PubChem CID

• 133021

ChemSpider

• 117391 ^N

Quick facts Legal status, Identifiers ...

Licofelone

Legal status
Legal status	Investigational
Identifiers
IUPAC name [6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl]acetic acid
CAS Number	156897-06-2
PubChem CID	133021
ChemSpider	117391 N
UNII	P5T6BYS22Y
ChEBI	CHEBI:47532
ChEMBL	ChEMBL52854
CompTox Dashboard (EPA)	DTXSID40166154
ECHA InfoCard	100.222.821
Chemical and physical data
Formula	C23H22ClNO2
Molar mass	379.88 g·mol−1
InChI InChI=1S/C23H22ClNO2/c1-23(2)13-19-22(15-6-4-3-5-7-15)21(16-8-10-17(24)11-9-16)18(12-20(26)27)25(19)14-23/h3-11H,12-14H2,1-2H3,(H,26,27) N Key:UAWXGRJVZSAUSZ-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Close

Licofelone is both an analgesic and an anti-inflammatory. Inhibition of 5-lipoxygenase (5-LOX) may reduce the gastrointestinal toxicity associated with other nonsteroidal anti-inflammatory drugs (NSAID), which only inhibit cyclooxygenase (COX). Licofelone is the first drug to inhibit both.

Phase III trials for osteoarthritis were conducted in the early 2000s,^[4][5] but results were mixed and the drug has never been submitted for regulatory approval.